CAS 720691-69-0: GSK-239512

GSK-239512 is an antagonist of H3 receptor and can be used in studies about the treatment of cognitive dysfunction in neurodegenerative disorders.

GSK-239512 is a potent and selective histamine H3 receptor antagonist, which is a compound developed by GSK, derived from extensive pharmacological research. This organic compound acts by selectively inhibiting the H3 receptor subtype, which modulates the release of neurotransmitters in the central nervous system, including histamine, acetylcholine, and norepinephrine. The pharmacological action of GSK-239512 involves attenuating the inhibitory action of histamine on neurotransmitter release, thereby increasing wakefulness and enhancing cognitive processes. This mechanism makes it a compelling candidate in the context of researching treatments for cognitive disorders such as Alzheimer's disease and attention-deficit hyperactivity disorder (ADHD). In preclinical studies, GSK-239512 has demonstrated encouraging results in improving cognition and memory. Its application extends to experimental models where modulating central histaminergic pathways is explored for therapeutic benefits. Current investigations aim to determine its efficacy and safety profiles in human clinical trials, where it continues to be pivotal in understanding histaminergic neuromodulation's role in cognitive enhancement and neuroprotection.

GSK-239512